Core Insights - The company reported a robust growth in revenue and profit for the first half of 2025, with a revenue of 3.113 billion yuan, representing a year-on-year increase of 22.5%, and a net profit attributable to the parent company of 1.182 billion yuan, up 20.2% year-on-year [1][2] - The company's gross margin for the first half of 2025 was 81.68%, a decrease of 0.72 percentage points, while the net profit margin was 37.99%, down 0.61 percentage points [1] - The company is a leader in collagen protein skincare products in China, focusing on R&D and expanding into eight consumer brands [2] Financial Performance - In the first half of 2025, the company's sales expense ratio improved by 1 percentage point to 34.01%, while the management expense ratio increased slightly by 0.07 percentage points to 2.65% [1] - The adjusted net profit for the first half of 2025 was 1.205 billion yuan, reflecting a year-on-year growth of 17.4% [1] Product and Brand Development - The company's flagship product line, "Kefumei," achieved a revenue of 2.54 billion yuan in the first half of 2025, marking a 22.7% increase year-on-year [1] - The company launched the "Zhenyu Mixin" series in 2025, focusing on post-surgical skin repair, which aligns well with its medical beauty channel strategy [1] - The "Keli Jin" brand generated a revenue of 500 million yuan in the first half of 2025, with a year-on-year growth of 26.9% [1] Sales Channels and Market Expansion - The direct sales channel generated 2.325 billion yuan in revenue, accounting for 74.7% of total revenue, with the DTC channel contributing 1.816 billion yuan [2] - The company has expanded its offline presence to approximately 1,700 public hospitals, 3,000 private hospitals and clinics, over 130,000 pharmacy stores, and around 6,000 CS/KA stores, including 24 specialty stores in key domestic cities [2] - The company has begun to penetrate the Southeast Asian market by entering Watsons in Malaysia [2] Investment Outlook - The company is expected to achieve net profits attributable to the parent company of 2.505 billion yuan, 3.102 billion yuan, and 3.732 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 21, 17, and 14 times [2]

Investment Rating - The report maintains a "Buy" rating for the company [4][7] Core Insights - The company achieved a revenue of 3.113 billion yuan in H1 2025, representing a year-on-year growth of 22.5%, and a net profit attributable to the parent company of 1.182 billion yuan, up 20.2% year-on-year [1] - The gross margin for H1 2025 was 81.68%, a slight decrease of 0.72 percentage points year-on-year, while the net margin was 37.99%, down 0.61 percentage points year-on-year [1] - The sales expense ratio improved by 1 percentage point year-on-year to 34.01%, while the management expense ratio increased by 0.07 percentage points to 2.65% [1] Revenue and Profit Growth - The company's brand "可复美" generated revenue of 2.54 billion yuan in H1 2025, with a year-on-year increase of 22.7% [2] - The "可丽金" brand achieved revenue of 500 million yuan, reflecting a growth of 26.9% year-on-year [2] Channel Performance - Direct sales channels contributed 2.325 billion yuan in revenue, accounting for 74.7% of total revenue, with DTC channels generating 1.816 billion yuan [3] - The company has expanded its offline presence, covering approximately 1,700 public hospitals and 3,000 private hospitals and clinics, along with over 130,000 pharmacy stores [3] Financial Forecast - The company is projected to achieve net profits of 2.505 billion yuan, 3.102 billion yuan, and 3.732 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 21, 17, and 14 [4][6]